18489517

Source:http://linkedlifedata.com/resource/pubmed/id/18489517

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0010181, umls-concept:C0205182
pubmed:issue	7
pubmed:dateCreated	2009-7-15
pubmed:abstractText	In 2002, the National Institute for Health and Clinical Excellence (NICE), recommended atypical antipsychotics over conventional ones for first-line schizophrenia treatment, based on their lower risk of extrapyramidal symptoms.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883818
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	1524-4733
pubmed:author	pubmed-author:BottemanMarcM, pubmed-author:BuskensErikE, pubmed-author:CaleoSueS, pubmed-author:DamenJoepJ, pubmed-author:HeegBartB, pubmed-author:InghamMikeM, pubmed-author:de CharroFrankF, pubmed-author:van HoutBenB
pubmed:issnType	Electronic
pubmed:volume	11
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1007-21
pubmed:meshHeading	pubmed-meshheading:18489517-Antipsychotic Agents, pubmed-meshheading:18489517-Cost-Benefit Analysis, pubmed-meshheading:18489517-Great Britain, pubmed-meshheading:18489517-Humans, pubmed-meshheading:18489517-Models, Biological, pubmed-meshheading:18489517-Models, Economic, pubmed-meshheading:18489517-Quality-Adjusted Life Years, pubmed-meshheading:18489517-Schizophrenia
pubmed:year	2008
pubmed:articleTitle	The cost-effectiveness of atypicals in the UK.
pubmed:affiliation	Pharmerit International, Rotterdam, The Netherlands. bheeg@pharmerit.com
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't